Skip to main content
letter
. 2016 Dec 30;19(3):454–456. doi: 10.1093/neuonc/now265

Fig. 1.

Fig. 1

T1-weighted contrast-enhanced MRI showing stable disease during (9/2014) and tumor progression after 6 cycles of maintenance temozolomide (11/2014). Tumor progression was confirmed by MR perfusion (bottom). The MRI scan 3 months after initiation of nivolumab treatment (3/2015) demonstrates increased contrast enhancement and pronounced edema. Subsequent MRI scans during ongoing nivolumab treatment indicate partial remission and durable tumor control.